Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iwashiro S, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S. Ikeda T, et al. Among authors: miyamoto s. J Thromb Thrombolysis. 2019 Nov;48(4):653-660. doi: 10.1007/s11239-019-01934-6. J Thromb Thrombolysis. 2019. PMID: 31432451 Free PMC article. Clinical Trial.
Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan.
Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T; MELT Japan Study Group. Ogawa A, et al. Among authors: miyamoto s. Stroke. 2007 Oct;38(10):2633-9. doi: 10.1161/STROKEAHA.107.488551. Epub 2007 Aug 16. Stroke. 2007. PMID: 17702958 Clinical Trial.
One-year atherothrombotic vascular events rates in outpatients with recent non-cardioembolic ischemic stroke: the EVEREST (Effective Vascular Event REduction after STroke) registry.
Suzuki N, Sato M, Houkin K, Terayama Y, Uchiyama S, Daida H, Shigematsu H, Goto S, Tanaka K, Origasa H, Miyamoto S, Minematsu K, Matsumoto M, Okada Y. Suzuki N, et al. Among authors: miyamoto s. J Stroke Cerebrovasc Dis. 2012 May;21(4):245-53. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.010. Epub 2012 Feb 24. J Stroke Cerebrovasc Dis. 2012. PMID: 22365283
Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society.
Minematsu K, Toyoda K, Hirano T, Kimura K, Kondo R, Mori E, Nakagawara J, Sakai N, Shiokawa Y, Tanahashi N, Yasaka M, Katayama Y, Miyamoto S, Ogawa A, Sasaki M, Suga S, Yamaguchi T; Japan Stroke Society. Minematsu K, et al. Among authors: miyamoto s. J Stroke Cerebrovasc Dis. 2013 Jul;22(5):571-600. doi: 10.1016/j.jstrokecerebrovasdis.2013.04.001. Epub 2013 May 31. J Stroke Cerebrovasc Dis. 2013. PMID: 23727456 Review.
Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry.
Ogawa S, Ikeda T, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iekushi K, Yamanaka S, Yamada T, Inuyama L; Rivaroxaban PostMarketing Surveillance Registry Investigators. Ogawa S, et al. Among authors: miyamoto s. J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2520-2526. doi: 10.1016/j.jstrokecerebrovasdis.2014.03.006. Epub 2014 Sep 20. J Stroke Cerebrovasc Dis. 2014. PMID: 25245483
Results of Prospective Cohort Study on Symptomatic Cerebrovascular Occlusive Disease Showing Mild Hemodynamic Compromise [Japanese Extracranial-Intracranial Bypass Trial (JET)-2 Study].
Kataoka H, Miyamoto S, Ogasawara K, Iihara K, Takahashi JC, Nakagawara J, Inoue T, Mori E, Ogawa A; JET-2 Investigators. Kataoka H, et al. Among authors: miyamoto s. Neurol Med Chir (Tokyo). 2015;55(6):460-8. doi: 10.2176/nmc.oa.2014-0424. Epub 2015 Jun 2. Neurol Med Chir (Tokyo). 2015. PMID: 26041628 Free PMC article.
3,361 results